2012
Sudden unexpected death in epilepsy in lamotrigine randomized‐controlled trials
Tomson T, Hirsch LJ, Friedman D, Bester N, Hammer A, Irizarry M, Ishihara L, Krishen A, Spaulding T, Wamil A, Leadbetter R. Sudden unexpected death in epilepsy in lamotrigine randomized‐controlled trials. Epilepsia 2012, 54: 135-140. PMID: 23030403, DOI: 10.1111/j.1528-1167.2012.03689.x.Peer-Reviewed Original ResearchConceptsSudden unexpected deathProbable SUDEPTreatment armsAntiepileptic drugsClinical trialsOdds ratioUnexpected deathTonic-clonic seizure frequencyRate of SUDEPRisk of SUDEPRandomized clinical trialsRandomized-controlled trialPotential risk factorsCause deathPossible SUDEPStudy medicationPatient yearsSeizure frequencyTreatment deathsComparator armActive comparatorNonrandomized studyUnadjusted ratesComparator groupRisk factors
2011
The effect of age and comedication on lamotrigine clearance, tolerability, and efficacy
Arif H, Svoronos A, Resor SR, Buchsbaum R, Hirsch LJ. The effect of age and comedication on lamotrigine clearance, tolerability, and efficacy. Epilepsia 2011, 52: 1905-1913. PMID: 21838791, DOI: 10.1111/j.1528-1167.2011.03217.x.Peer-Reviewed Original ResearchConceptsLTG clearanceOlder adultsYoung adultsOlder patientsSeizure freedomYounger patientsAdverse effectsOne-year retentionEfficacy of lamotrigineIntolerable side effectsHigher serum levelsSpecific adverse effectsSignificant adverse effectsLamotrigine clearanceEffect of ageApparent clearanceSerum levelsLTG levelsOldest tertileAdult outpatientsSide effectsPatientsLamotrigineEnzyme inducersIntolerability
2010
Comparative Effectiveness of 10 Antiepileptic Drugs in Older Adults With Epilepsy
Arif H, Buchsbaum R, Pierro J, Whalen M, Sims J, Resor SR, Bazil CW, Hirsch LJ. Comparative Effectiveness of 10 Antiepileptic Drugs in Older Adults With Epilepsy. JAMA Neurology 2010, 67: 408-415. PMID: 20385905, DOI: 10.1001/archneurol.2010.49.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAminesAnticonvulsantsCarbamazepineCyclohexanecarboxylic AcidsDose-Response Relationship, DrugDrug ResistanceEpilepsyFemaleFructoseGabapentinGamma-Aminobutyric AcidHumansLamotrigineLevetiracetamMaleMiddle AgedOxcarbazepinePhenytoinPiracetamRetrospective StudiesTopiramateTreatment OutcomeTriazinesConceptsSeizure freedom ratesAntiepileptic drugsSeizure freedomOlder adultsOverall groupColumbia Comprehensive Epilepsy CenterAdverse effectsIntolerable adverse effectsFirst antiepileptic drugPercentage of patientsComprehensive Epilepsy CenterEffective antiepileptic drugGastrointestinal symptomsRefractory diseaseMore patientsRetrospective reviewEpilepsy centersMAIN OUTCOMEDose changesPatientsComparative effectivenessMore monthsOxcarbazepineLevetiracetamRetention rate
2006
Lamotrigine and its applications in the treatment of epilepsy and other neurological and psychiatric disorders
Malik S, Arif H, Hirsch LJ. Lamotrigine and its applications in the treatment of epilepsy and other neurological and psychiatric disorders. Expert Review Of Neurotherapeutics 2006, 6: 1609-1627. PMID: 17144777, DOI: 10.1586/14737175.6.11.1609.Peer-Reviewed Original ResearchConceptsBroad-spectrum antiepileptic drugBipolar disorder type ILennox-Gastaut syndromeTreatment of epilepsySerious skin rashesTreatment of womenFavorable pharmacokinetic propertiesConcomitant medicationsNeuropathic painElderly patientsSkin rashAdjunctive treatmentDose adjustmentGeneralized seizuresPartial seizuresAntiepileptic drugsSlow titrationNeurological conditionsPsychiatric disordersAdult populationLamotriginePharmacokinetic propertiesSmall riskPreliminary dataEpilepsyPredictors of Lamotrigine‐associated Rash
Hirsch LJ, Weintraub DB, Buchsbaum R, Spencer HT, Straka T, Hager M, Resor SR. Predictors of Lamotrigine‐associated Rash. Epilepsia 2006, 47: 318-322. PMID: 16499755, DOI: 10.1111/j.1528-1167.2006.00423.x.Peer-Reviewed Original ResearchConceptsAntiepileptic drugsRisk factorsColumbia Comprehensive Epilepsy CenterDrug-related rashStevens-Johnson syndromeToxic epidermal necrolysisComprehensive Epilepsy CenterHistory of rashGreatest risk factorEpidermal necrolysisSevere rashEpilepsy centersMedical historyRemote historyRetrospective analysisRashMedication variablesMultivariate analysisPotential predictorsPatientsStrongest predictorPredictorsLTGTitration rateChildren
2005
Effect of Antiepileptic Drug Comedication on Lamotrigine Clearance
Weintraub D, Buchsbaum R, Resor SR, Hirsch LJ. Effect of Antiepileptic Drug Comedication on Lamotrigine Clearance. JAMA Neurology 2005, 62: 1432-1436. PMID: 16157751, DOI: 10.1001/archneur.62.9.1432.Peer-Reviewed Original ResearchConceptsLamotrigine clearanceLamotrigine serum concentrationsNewer AEDsSerum concentrationsColumbia Comprehensive Epilepsy CenterComprehensive Epilepsy CenterLamotrigine monotherapyAdjunctive therapyMedical chartsEpilepsy centersComedicationMonotherapyBody weightPhenytoinValproatePatientsML/hAEDsClearanceSignificant predictorsCarbamazepineOxcarbazepinePredictorsLamotrigineTherapy
2004
Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy
Hirsch LJ, Weintraub D, Du Y, Buchsbaum R, Spencer HT, Hager M, Straka T, Bazil CW, Adams DJ, Resor SR, Morrell MJ. Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology 2004, 63: 1022-1026. PMID: 15452293, DOI: 10.1212/01.wnl.0000138424.33979.0c.Peer-Reviewed Original ResearchMeSH KeywordsAnticonvulsantsDose-Response Relationship, DrugDrug EruptionsDrug InteractionsDrug Therapy, CombinationEpilepsyFemaleGastrointestinal DiseasesHeadacheHumansLamotrigineMaleMental DisordersNervous System DiseasesRetrospective StudiesSleep Initiation and Maintenance DisordersTriazinesValproic AcidConceptsLamotrigine serum concentrationsSpecific side effectsAntiepileptic drugsSide effectsSerum levelsLTG levelsSerum concentrationsColumbia Comprehensive Epilepsy CenterConcomitant antiepileptic drugsLTG serum levelsComprehensive Epilepsy CenterRates of toxicityDuration of useInitial target rangeAED regimensRefractory patientsToxic regimenConcurrent medicationsSeizure freedomAdditional efficacyClinical toxicityEpilepsy centersLTG concentrationsClinical trialsDose changes